COST-EFFECTIVENESS ANALYSIS OF NOVEL THERAPIES FOR HER2+METASTATIC BREAST CANCER: [FAM-] TRASTUZUMAB DERUXTECAN VERSUS TUCATINIB TRASTUZUMAB AND CAPECITABINE COMBINATION

Vondeling, G; Palaka, E; Livings, C; Naik, J; Sullivan, W

VALUE IN HEALTH, 2020; 23 (): S433